欧康维视生物-B(01477)：OT-703于海南博鳌进行的真实世界研究完成患者入组

智通财经01-20

智通财经APP讯，欧康维视生物-B(01477)发布公告，本集团产品OT-703(ILUVIEN®，氟轻松玻璃体植入剂)(是一款可注射的、非生物降解的氟轻松玻璃体植入剂，用于治疗糖尿病性黄斑水肿(DME))最近已完成于中华人民共和国海南省博鳌乐城国际医疗旅游先行区进行的真实世界研究合共195例患者的入组。OT-703(即190微克氟轻松玻璃体内植入剂(0.19毫克))是一款可注射的、非生物降解的氟...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2604615931?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-20 07:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604615931","market":"sh","top_or_hot":-1,"title":"欧康维视生物-B(01477)：OT-703于海南博鳌进行的真实世界研究完成患者入组","media":"智通财经","content":"<div>\n<p>智通财经APP讯，欧康维视生物-B(01477)发布公告，本集团产品OT-703(ILUVIEN®，氟轻松玻璃体植入剂)(是一款可注射的、非生物降解的氟轻松玻璃体植入剂，用于治疗糖尿病性黄斑水肿(DME))最近已完成于中华人民共和国海南省博鳌乐城国际医疗旅游先行区进行的真实世界研究合共195例患者的入组。OT-703(即190微克氟轻松玻璃体内植入剂(0.19毫克))是一款可注射的、非生物降解的氟...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1394801.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>欧康维视生物-B(01477)：OT-703于海南博鳌进行的真实世界研究完成患者入组</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n欧康维视生物-B(01477)：OT-703于海南博鳌进行的真实世界研究完成患者入组\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-20 07:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1394801.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，欧康维视生物-B(01477)发布公告，本集团产品OT-703(ILUVIEN®，氟轻松玻璃体植入剂)(是一款可注射的、非生物降解的氟轻松玻璃体植入剂，用于治疗糖尿病性黄斑水肿(DME))最近已完成于中华人民共和国海南省博鳌乐城国际医疗旅游先行区进行的真实世界研究合共195例患者的入组。OT-703(即190微克氟轻松玻璃体内植入剂(0.19毫克))是一款可注射的、非生物降解的氟...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1394801.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1394801.html","article_id":"2604615931","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604615931","pubTimestamp":1768865436,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，欧康维视生物-B 发布公告，本集团产品OT-703最近已完成于中华人民共和国海南省博鳌乐城国际医疗旅游先行区进行的真实世界研究合共195例患者的入组。其已获得美国食品药品监督管理局 的监管批准，并以商号“ILUVIEN”上市。OT-703是FDA批准的唯一一款缓释长达3年的治疗DME的皮质类固醇眼内植入剂。于2023年12月，OT-703获得香港药剂业及毒药管理局的批准，可根据香港法例第 138章《药剂业及毒药条例》在香港注册为医药产品。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","BK1574":"生物医药B类股","01477":"欧康维视生物-B"},"translate_title":"Oconvision Bio-B (01477): Patient enrollment completed in the real-world study of OT-703 in Boao, Hainan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1.5},"content_text":"智通财经APP讯，欧康维视生物-B(01477)发布公告，本集团产品OT-703(ILUVIEN®，氟轻松玻璃体植入剂)(是一款可注射的、非生物降解的氟轻松玻璃体植入剂，用于治疗糖尿病性黄斑水肿(DME))最近已完成于中华人民共和国海南省博鳌乐城国际医疗旅游先行区进行的真实世界研究合共195例患者的入组。OT-703(即190微克氟轻松玻璃体内植入剂(0.19毫克))是一款可注射的、非生物降解的氟轻松玻璃体植入剂，通过于眼部连续缓释最多36个月的微量非专有皮质类固醇醋酸氟轻松(FAc)治疗DME。其已获得美国食品药品监督管理局(FDA) 的监管批准，并以商号“ILUVIEN®”上市。OT-703是FDA批准的唯一一款缓释长达3年的治疗DME的皮质类固醇眼内植入剂。于2021年4月，本公司与Alimera Sciences, Inc.(Alimera)订立一份独家许可协议，据此，本公司自Alimera获得 ILUVIEN®在大中华区、韩国及东南亚11个国家的独家开发及商业化许可权利。于2023年12月，OT-703获得香港药剂业及毒药管理局的批准，可根据香港法例第 138章《药剂业及毒药条例》在香港注册为医药产品。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604615931","isCrawlerRequest":true}